Table 2.
Comparison of antitumour protection between wild-type and codon-optimized E7 genes delivered in the lysosome-targeting vector
| Days post tumour challenge1 | ||||||||
|---|---|---|---|---|---|---|---|---|
| Plasmids | 8 | 12 | 15 | 19 | 22 | 25 | 30 | 35 |
| Neg. control (pLacZ) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Sig/E7/LAMP | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 |
| Sig/sE7/LAMP | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 02 |
Each group of mice (n = 10) was immunized i.m. with 50 μg pcDNA3-Sig/E7/LAMP and pcDNA3-Sig/sE7/LAMP at 0, 2 and 6 weeks and then challenged s.c. with 5 × 104 TC-1 tumour cells per mouse at 8 weeks. Mice were counted for tumour formation over time.
1
The values represent the number of animals with tumour; the number of animals challenged each time being 10.
2
Statistically significant using Chi-square test at P < 0·05 compared to pcDNA3-Sig/E7/LAMP.